ticagrelor

EuroPCR 2019 | Global Leaders: La monoterapia con ticagrelor a largo plazo podría tener un lugar en angioplastias complejas.

EuroPCR 2019 | Global Leaders: Ticagrelor Monotherapy at Long Term Could Have a Role in Complex PCI

This post hoc analysis of what had been a trial with negative outcomes should be considered only as a hypothesis generator. Patients receiving complex PCI treated with ticagrelor monotherapy after one-month dual antiaggregation therapy (DAPT) showed better results at 2 years when compared against patients receiving a conventional DAPT scheme. In the global analysis, this<a href="https://solaci.org/en/2019/05/23/europcr-2019-global-leaders-ticagrelor-monotherapy-at-long-term-could-have-a-role-in-complex-pci/" title="Read more" >...</a>

The First Antidote Against Ticagrelor Is a Rapid-Acting, Extended Effect Agent in Preliminary Results

This study attempts to test drug PB2452 for use in cases of catastrophic bleeding and, then, its potential use in other scenarios involving patients receiving ticagrelor. This specific ticagrelor reversal agent stops immediately and substantially the effect of the aforementioned P2Y12 receptor antagonist according to several test measurements conducted during this phase 1 trial in<a href="https://solaci.org/en/2019/05/16/the-first-antidote-against-ticagrelor-is-a-rapid-acting-extended-effect-agent-in-preliminary-results/" title="Read more" >...</a>

GLOBAL LEADERS: El ticagrelor como monoterapia no supera a los esquemas clásicos post angioplastia

ESC 2018 | GLOBAL LEADERS: Ticagrelor Monotherapy Is Not Superior to Classic Therapies After Angioplasty

Dropping aspirin after the first month and continuing with ticagrelor monotherapy was not better than standard dual antiplatelet therapy (aspirin plus ticagrelor or clopidogrel) in patients who underwent coronary angioplasty. Patrick Serruys presented this work (which was simultaneously published in The Lancet) at the European Society of Cardiology (ESC) Congress 2018 and explained that, given<a href="https://solaci.org/en/2018/08/30/esc-2018-global-leaders-ticagrelor-monotherapy-is-not-superior-to-classic-therapies-after-angioplasty/" title="Read more" >...</a>

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

First Results for Ticagrelor in Elective Coronary Angioplasty

This is one of the first studies on the use of ticagrelor in patients with stable coronary arteries who undergo elective angioplasty. Although its number of patients is low and its endpoints are soft, this work at least provides some support to what is already happening in daily clinical practice. Many patients admitted for a<a href="https://solaci.org/en/2018/06/27/first-results-for-ticagrelor-in-elective-coronary-angioplasty/" title="Read more" >...</a>

ACC 2018 | TREAT: Ticagrelor + Fibrinolytics’ Effect on Bleeding

Ticagrelor seems as safe as clopidogrel in patients undergoing ST elevation MI treated with fibrinolytics, at least in terms of TIMI major bleeding at 30 days. Longer follow up will help determine whether there are differences in efficacy or safety issues, as stated by the presenter Otavio Berwanger. This study was presented at ACC 2018 scientific sessions<a href="https://solaci.org/en/2018/04/08/acc-2018-treat-ticagrelor-fibrinolytics-effect-on-bleeding/" title="Read more" >...</a>

THEMIS: eventos isquémicos y hemorrágicos en difícil equilibrio para el ticagrelor crónico

New Study Shows Ticagrelor + Aspirin Reduce Events Rate

Just when we were starting to understand how long dual antiplatelet therapy should be for our patients,&nbsp;JACC&nbsp;publishes this study where ticagrelor&nbsp;combined with aspirin significantly reduces relative and absolute events rate at long term, especially in patients with multivessel disease. The PEGASUS-TIMI 54 assessed the long-term benefits of two different doses of ticagrelor (60 mg or<a href="https://solaci.org/en/2018/03/21/new-study-shows-ticagrelor-aspirin-reduce-events-rate/" title="Read more" >...</a>

ticagrelor-clopidogrel-compressor

Clopidogrel or Ticagrelor in Patients with Acute Coronary Syndrome Treated with New-Generation DES: CHANGE DAPT

Courtesy of Dr. Pablo Baglioni. This is a prospective observational study with a 1-year follow-up analyzing 2062 patients with acute coronary syndrome (ACS)&nbsp;who have been treated with coronary angioplasty using new-generation drug-eluting stents (DES). Patients were included between December 21, 2012 and August 25, 2015. On May, 2014, due to changes in international guidelines, clopidogrel<a href="https://solaci.org/en/2017/12/15/clopidogrel-or-ticagrelor-in-patients-with-acute-coronary-syndrome-treated-with-new-generation-des-change-dapt/" title="Read more" >...</a>

DACAB: Ticagrelor and Aspirin Improve Vein Graft Patency

According to this Chinese study,&nbsp;dual antiplatelet therapy&nbsp;with&nbsp;ticagrelor&nbsp;and&nbsp;aspirin&nbsp;improves vein graft patency a year after surgery without increasing the risk for major bleeding. &nbsp; Treatment with the P2Y12 inhibitor ticagrelor in combination with aspirin has been widely accepted for patients with acute coronary syndrome undergoing angioplasty. However, there were no related data regarding surgical revascularization. Read also:&nbsp;&#8220;Ticagrelor<a href="https://solaci.org/en/2017/11/16/dacab-ticagrelor-and-aspirin-improve-vein-graft-patency-2/" title="Read more" >...</a>

ticagrelor vs clopidogrel en enfermedad vascular periferica

Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Vascular Disease

Peripheral vascular disease is considered as a manifestation of systemic atherosclerosis associated with adverse events, both cardiovascular and related to the lower limbs. &nbsp; Previous studies showed that clopidogrel monotherapy is associated with lower risk of events when compared to low doses of aspirin. Such is the rationale behind this article comparing clopidogrel and ticagrelor<a href="https://solaci.org/en/2017/01/04/ticagrelor-versus-clopidogrel-in-symptomatic-peripheral-vascular-disease/" title="Read more" >...</a>

ticagrelor vs prasugel

Ticagrelor vs. Prasugel: Similar Safety and Efficacy in Primary Angioplasty

No randomized head-to-head study comparing the efficacy and safety of ticagrelor and prasugrel has been carried out in the last 7&nbsp;years since these newer P2Y12 inhibitors first showed a higher efficacy relative to clopidogrel. &nbsp; This study was designed to compare the efficacy and safety of prasugrel and ticagrelor in patients with acute myocardial infarction<a href="https://solaci.org/en/2016/12/07/ticagrelor-vs-prasugel-primary-angioplasty/" title="Read more" >...</a>

Top